BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

820 related articles for article (PubMed ID: 17387156)

  • 21. Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.
    Tamma PD; Han JH; Rock C; Harris AD; Lautenbach E; Hsu AJ; Avdic E; Cosgrove SE;
    Clin Infect Dis; 2015 May; 60(9):1319-25. PubMed ID: 25586681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Mortality risk factors for bloodstream infections caused by extended-spectrum beta-lactamase-producing microorganisms].
    Ferrández O; Grau S; Saballs P; Luque S; Terradas R; Salas E
    Rev Clin Esp; 2011 Mar; 211(3):119-26. PubMed ID: 21371702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors and outcome of extended-spectrum β-lactamase-producing Enterobacter cloacae bloodstream infections.
    Qureshi ZA; Paterson DL; Pakstis DL; Adams-Haduch JM; Sandkovsky G; Sordillo E; Polsky B; Peleg AY; Bhussar MK; Doi Y
    Int J Antimicrob Agents; 2011 Jan; 37(1):26-32. PubMed ID: 21075605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection.
    Hyle EP; Lipworth AD; Zaoutis TE; Nachamkin I; Bilker WB; Lautenbach E
    Arch Intern Med; 2005 Jun; 165(12):1375-80. PubMed ID: 15983286
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk factors for bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Wu UI; Yang CS; Chen WC; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2010 Aug; 43(4):310-6. PubMed ID: 20688291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Does Quick Sepsis-Related Organ Failure Assessment Suggest the Use of Initial Empirical Carbapenem Therapy in Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Bacteria? :A Multicenter Case-Control Study.
    Mitsuboshi S; Tsuruma N; Watanabe K; Takahashi S; Nakashita M; Ito A; Kobayashi K; Tsugita M
    Jpn J Infect Dis; 2019 Mar; 72(2):124-126. PubMed ID: 30381688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases.
    Rodríguez-Baño J; Miró E; Villar M; Coelho A; Gozalo M; Borrell N; Bou G; Conejo MC; Pomar V; Aracil B; Larrosa N; Agüero J; Oliver A; Fernández A; Oteo J; Pascual A; Navarro F
    J Infect; 2012 Feb; 64(2):176-83. PubMed ID: 22138600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae.
    Falcone M; Vena A; Mezzatesta ML; Gona F; Caio C; Goldoni P; Trancassini AM; Conti C; Orsi GB; Carfagna P; Stefani S; Venditti M
    Ann Ig; 2014; 26(4):293-304. PubMed ID: 25001119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.
    Zarkotou O; Pournaras S; Tselioti P; Dragoumanos V; Pitiriga V; Ranellou K; Prekates A; Themeli-Digalaki K; Tsakris A
    Clin Microbiol Infect; 2011 Dec; 17(12):1798-803. PubMed ID: 21595793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
    Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
    J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.
    Tumbarello M; Viale P; Viscoli C; Trecarichi EM; Tumietto F; Marchese A; Spanu T; Ambretti S; Ginocchio F; Cristini F; Losito AR; Tedeschi S; Cauda R; Bassetti M
    Clin Infect Dis; 2012 Oct; 55(7):943-50. PubMed ID: 22752516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for multidrug resistance in nosocomial bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Park SY; Kang CI; Joo EJ; Ha YE; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2012 Oct; 18(5):518-24. PubMed ID: 22742454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of mortality from community-onset bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae.
    Apisarnthanarak A; Kiratisin P; Mundy LM
    Infect Control Hosp Epidemiol; 2008 Jul; 29(7):671-4. PubMed ID: 18624669
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
    Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
    Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Control of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a children's hospital by changing antimicrobial agent usage policy.
    Lee J; Pai H; Kim YK; Kim NH; Eun BW; Kang HJ; Park KH; Choi EH; Shin HY; Kim EC; Lee HJ; Ahn HS
    J Antimicrob Chemother; 2007 Sep; 60(3):629-37. PubMed ID: 17599919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae blood isolates with inducible AmpC β-lactamase.
    Cheong HS; Ko KS; Kang CI; Chung DR; Peck KR; Song JH
    Microb Drug Resist; 2012 Aug; 18(4):446-52. PubMed ID: 22409779
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.
    Ben-Ami R; Rodríguez-Baño J; Arslan H; Pitout JD; Quentin C; Calbo ES; Azap OK; Arpin C; Pascual A; Livermore DM; Garau J; Carmeli Y
    Clin Infect Dis; 2009 Sep; 49(5):682-90. PubMed ID: 19622043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome.
    Nasa P; Juneja D; Singh O; Dang R; Singh A
    Eur J Intern Med; 2012 Mar; 23(2):192-5. PubMed ID: 22284253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.